Australia's most trusted
source of pharma news
Thursday, 03 April 2025
Posted 1 April 2025 AM
AstraZeneca's rare disease business Alexion has scored a win this month with Ultomiris becoming the first targeted treatment option to be reimbursed for Australians living with neuromyelitis optica spectrum disorder (NMOSD).
The PBS expansion, effective from today, covers patients with anti-aquaporin 4 antibody-positive NMOSD who have experienced a recent relapse event, despite prior treatment with rituximab or who cannot tolerate rituximab.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.